[HTML][HTML] White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA

…, T Teeling, L Cypers, L Cools, LH Bjermer… - Frontiers in …, 2022 - frontiersin.org
Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients
with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD)…

How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

EM Kerwin, PW Jones, LH Bjermer… - Chronic Respiratory …, 2023 - journals.sagepub.com
This review addresses outstanding questions regarding initial pharmacological management
of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves …

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial

…, EM Kerwin, LH Bjermer… - Therapeutic …, 2020 - journals.sagepub.com
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …

[HTML][HTML] Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

…, L Tombs, C Compton, DA Lipson, LH Bjermer - Respiratory …, 2021 - Springer
Background In patients with chronic obstructive pulmonary disease (COPD), the
relationship between short-term bronchodilator reversibility and longer-term response to …

Bronchodilator Responsiveness Measured by Spirometry and Impulse Oscillometry in Patients with Asthma After Short Acting Antimuscarinic and/or Beta-2-Agonists …

NMD van der Burg, C Ekelund, LH Bjermer… - Journal of Asthma …, 2024 - Taylor & Francis
Background Bronchodilator responsiveness (BDR) in asthma involves both the central and
peripheral airways but is primarily relieved with beta-2-agonists and evaluated by spirometry. …

[HTML][HTML] Efficacy and safety of umeclidinium/vilanterol in current and former smokers with COPD: a prespecified analysis of the EMAX trial

LH Bjermer, IH Boucot, CF Vogelmeier, F Maltais… - Advances in …, 2021 - Springer
Bjermer has received honoraria for giving a lecture or attending an advisory board for
Airsonett, ALK-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Meda, Novartis, and Teva…

Comparative efficacy and safety of umeclidinium/vilanterol, umeclidinium and salmeterol in symptomatic maintenance-naïve and maintenance-treated chronic …

LH Bjermer, E Kerwin, F Maltais, P Jones… - B45. COPD …, 2019 - atsjournals.org
Rationale: In symptomatic, low exacerbation risk patients with chronic obstructive
pulmonary disease (COPD), long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist …

COPD-specific chondroitin sulfate modifications are linked to TGF-B1

…, A Nybom, XH Zhou, LH Bjermer… - C108. COPD …, 2019 - atsjournals.org
Rationale: Chronic Obstructive Pulmonary Disease (COPD) is characterized by extensive
structural remodelling with alterations of cell and tissue architecture as well as in extracellular …

Disease-Specific Alterations in Glycosaminoglycans in IPF and COPD

…, XH Zhou, G Dellgren, LH Bjermer… - C72. PULMONARY …, 2018 - atsjournals.org
Rationale: Glycosaminoglycans (GAGs) are an important structural component in the
extracellular matrix. They are, in addition, involved in tissue repair by the ability to bind and …

Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed to Treat Analysis of the EMAX Trial

LH Bjermer, F Maltais, C Vogelmeier… - B41. THERAPEUTIC …, 2020 - atsjournals.org
Rationale: The number needed to treat (NNT) indicates the number of patients who need to
be treated for one additional responder to be seen with one therapy compared with another …